Exservan (riluzole) Oral Film Amyotrophic Lateral Sclerosis Approved FDA Approval announced November 22, 2019.
Sympazan Lennox-Gastaut Syndrome Approved Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Libervant - AQST-203 Epileptic seizures PDUFA PDUFA date September 27, 2020.
AQST-119 Erectile dysfunction CRL CRL issued November 16, 2018.
APL-130277 Parkinson’s Disease with motor fluctuations PDUFA CRL issued January 30, 2019 through partner Sunovion (private company). NDA refiled. New PDUFA date May 21, 2020.
AQST-108 Anaphylaxis Phase 1 Pivotal pharmacokinetic (PK) trials to be initiated before the end of 2020
Simplified version, click on link...
https://www.biopharmcatalyst.com/company/AQST
Be sure to CLICK ON DRUG INFORMATION
Recent AQST News
- Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024 • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 06/12/2024 09:14:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 04:36:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 04:35:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 12:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:52 PM
- Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 05:40:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 05:40:07 PM
- Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:23:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:21:49 PM
- Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/07/2024 08:19:11 PM
- Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film • GlobeNewswire Inc. • 04/29/2024 11:00:00 AM
- Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology • GlobeNewswire Inc. • 04/12/2024 08:01:00 PM
- Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock • GlobeNewswire Inc. • 03/25/2024 12:00:25 PM
- Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock • GlobeNewswire Inc. • 03/20/2024 01:49:43 AM
- Aquestive Therapeutics Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/19/2024 08:01:00 PM
- Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting • GlobeNewswire Inc. • 03/14/2024 09:23:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:36:35 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM